Jiaming Qian
Peking Union Medical College
7 Papers
47 Citations
Jiaming Qian is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Inflammatory bowel disease & Tuberculosis. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia
Zhihua Ran,Kaichun Wu,Katsuyoshi Matsuoka,Yoon Tae Jeen,Shu-Chen Wei,Vineet Ahuja,Minhu Chen,Pin Jin Hu,Akira Andoh,Hyo Jong Kim,Suk-Kyun Yang,Mamoru Watanabe,Siew C. Ng,Toshifumi Hibi,Ida Hilmi,Yasuo Suzuki,Dong Soo Han,Wai K. Leung,Jose D. Sollano,Choon Jin Ooi,Jiaming Qian +20 more
TL;DR: The recommendations encompass pretreatment evaluation;medical management of active IBD; medical management of IBD in remission; management ofIBD during the periconception period and pregnancy; surveillance strategies for colitis‐associated cancer; monitoring side effects of thiopurines and methotrexate; and infections in IBD.
61
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.
Dong Il Park,Tadakazu Hisamatsu,Minhu Chen,Siew C. Ng,Choon Jin Ooi,Shu-Chen Wei,Rupa Banerjee,Ida Hilmi,Yoon Tae Jeen,Dong Soo Han,Hyo Jong Kim,Zhihua Ran,Kaichun Wu,Jiaming Qian,Pin Jin Hu,Katsuyoshi Matsuoka,Akira Andoh,Yasuo Suzuki,Kentaro Sugano,Mamoru Watanabe,Toshifumi Hibi,Amarender Singh Puri,Suk-Kyun Yang +22 more
TL;DR: These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.
Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment
Dong I.I. Park,Tadakazu Hisamatsu,Minhu Chen,Siew C. Ng,Choon Jin Ooi,Shu-Chen Wei,Rupa Banerjee,Ida Hilmi,Yoon Tae Jeen,Dong Soo Han,Hyo Jong Kim,Zhihua Ran,Kaichun Wu,Jiaming Qian,Pin Jin Hu,Katsuyoshi Matsuoka,Akira Andoh,Yasuo Suzuki,Kentaro Sugano,Mamoru Watanabe,Toshifumi Hibi,Amarender Singh Puri,Suk-Kyun Yang +22 more
TL;DR: In this paper, the authors developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment.
35
Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment: AOCC & APAGE consensus on TB in IBD-Part 1
Dong Ii Park,Tadakazu Hisamatsu,Minhu Chen,Siew C. Ng,Choon Jin Ooi,Shu-Chen Wei,Rupa Banerjee,Ida Hilmi,Yoon Tae Jeen,Dong Soo Han,Hyo Jong Kim,Zhihua Ran,Kaichun Wu,Jiaming Qian,Pinjin Hu,Katsuyoshi Matsuoka,Akira Andoh,Yasuo Suzuki,Kentaro Sugano,Mamoru Watanabe,Toshifumi Hibi,Amarender Singh Puri,Suk-Kyun Yang +22 more
22
The safety and efficacy of infliximab in patients with active ulcerative colitis in China
Baili Chen,Jiaming Qian,Kai-Chun Wu,Jianqiu Sheng,Jianming Xu,Zhihua Ran,Yaozong Yuan,Huahong Wang,Zhifen Chen,Zhao-Shen Li,Chengwei Tang,Xiaohua Hou,Yanyan Hou,Chen Minhu +13 more
- 25 Apr 2017
TL;DR: Infliximab 5 mg/kg was safe and efficacious in Chinese patients with moderate-to-severe ulcerative colitis and there were no drug-related serious adverse events during the study.
4